New hope for rare liver cancer: drug duo targets tumor fuel
NCT ID NCT06027086
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining a glutamine-blocking drug (DRP-104) with an immunotherapy (durvalumab) can shrink or control advanced fibrolamellar carcinoma, a rare liver cancer. About 27 people aged 12 and older whose cancer has worsened despite prior treatment will receive the drugs. The main goals are safety and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Johns Hopkins SKCCC
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.